Key Takeaways
- The University of Pennsylvania’s new AIRFoundry is an NSF‑funded RNA biofoundry that provides a one‑stop facility for designing and building RNA‑based products.
- Backed by an $18 million federal grant (six‑year award starting September 2024), it builds on Penn’s Nobel‑Prize‑winning mRNA COVID‑19 vaccine platform.
- Artificial intelligence is being integrated to automate design, synthesis, and manufacturing processes, aiming to democratize RNA technology for academia and industry worldwide.
- Current projects include fish vaccines, plant‑protective RNA that induces heat‑shock proteins, and transient RNA‑based pest control alternatives to chemical pesticides.
- The foundry operates on a fee‑for‑service model, with the goal of becoming self‑sustaining while training the next generation of scientists to view RNA as a versatile problem‑solving tool.
Introduction and Overview of AIRFoundry
The recently launched NSF AIRFoundry at the University of Pennsylvania represents a strategic expansion of the United States’ biotechnological infrastructure. Situated in One uCity Square in University City, the facility opened in March and offers a centralized hub where researchers can design, synthesize, and test ribonucleic acid (RNA) molecules for a variety of applications. By consolidating expertise, equipment, and protocols under one roof, the foundry seeks to lower the barriers that have historically limited RNA‑based innovation to well‑funded labs.
Funding and Federal Support
AIRFoundry’s operations are underwritten by an $18 million grant from the National Science Foundation, part of a broader initiative that has established five specialized biofoundries across the nation. The award, which commenced in September 2024, provides six years of funding to develop the foundry’s core capabilities. Principal Investigator Daeyeon Lee, a professor of chemical and biomolecular engineering at Penn, emphasizes that the grant is intended to jump‑start the facility, with the expectation that service revenues will eventually render it self‑sustaining.
Mission to Democratize RNA Technology
Lee repeatedly stresses the foundry’s guiding principle: “We need to democratize this technology.” By offering fee‑for‑service access to state‑of‑the‑art RNA synthesis and characterization tools, AIRFoundry aims to make advanced RNA engineering available not only to large pharmaceutical companies but also to academic labs, start‑ups, and agricultural researchers who might lack the capital to build their own infrastructure. This democratization is envisioned as a catalyst for a broader range of scientific and commercial breakthroughs.
Connection to Nobel Prize‑Winning mRNA Work
The foundry builds directly upon Penn’s legacy in mRNA technology, highlighted by the 2023 Nobel Prize awarded to Katalin Karikó and Drew Weissman for their pioneering contributions that enabled the first COVID‑19 vaccines. Weissman’s earlier, smaller‑scale mRNA production setup served as a proof‑of‑concept for the foundry’s larger ambition. The new facility scales up those capabilities, providing the sterile environment and specialized expertise needed to produce high‑quality RNA at greater volumes.
AI Integration (AIRFoundry Acronym)
The name AIRFoundry stands for Artificial Intelligence‑driven RNA BioFoundry, reflecting a core strategy to weave machine learning into every stage of the RNA development pipeline. Researchers plan to use AI to mine existing literature, optimize sequence designs, predict secondary structures, and streamline synthesis protocols. Ultimately, the vision is for users to walk into the physical lab, upload a design, and let AI‑guided robots handle the labor‑intensive steps of RNA assembly and purification.
Impact of Political/Funding Challenges
Despite the foundry’s promise, the broader mRNA field has faced headwinds. In the preceding year, Health and Human Services Secretary Robert F. Kennedy Jr. redirected $500 million away from mRNA vaccine development, citing safety concerns that contradict extensive scientific consensus. Lee acknowledges these political pressures but notes that AIRFoundry’s diversified portfolio—spanning health, agriculture, and industrial applications—helps insulate the facility from reliance on any single funding stream or policy decision.
Expanding Applications: Healthcare, Agriculture, and Beyond
AIRFoundry’s scientists are actively pursuing RNA solutions beyond infectious disease vaccines. In healthcare, they explore therapeutic RNAs for rare genetic disorders and cancer immunotherapy. In agriculture, the focus shifts to safeguarding crops and livestock through biologically based, environmentally friendly interventions. The foundry’s interdisciplinary approach encourages cross‑pollination of ideas, allowing insights from one sector to inspire innovations in another.
Fish Vaccines Project
One concrete collaboration involves developing RNA‑based vaccines to keep fish healthy in aquaculture settings. Traditional fish vaccines often rely on inactivated pathogens or live attenuated strains, which can be costly and raise concerns about residual virulence. By delivering mRNA that encodes specific antigenic proteins, the foundry aims to stimulate a robust immune response in fish without introducing live pathogens, potentially reducing disease losses and the need for antibiotics in farms.
Plant Heat Shock Protein and Pest Control
Another promising line of work targets plant resilience. Researchers are designing RNA molecules that instruct plant cells to produce heat‑shock proteins, which protect cellular machinery during extreme temperature spikes. Because the RNA degrades naturally over weeks, the protective effect is temporary—ideal for application during hot summer months, after which the molecule dissipates before harvest. This transient nature also opens the door to RNA‑based pest control: sequences could be engineered to disrupt essential genes in insects or fungi, offering a biodegradable alternative to synthetic pesticides that persist in the environment.
Fee-for-Service Model and Future Self‑Sustainability
Currently, AIRFoundry operates on a fee‑for‑service basis: external partners submit a desired RNA construct, and the foundry’s team handles design, synthesis, quality control, and delivery. This model not only generates revenue to cover operating costs but also provides valuable feedback that informs continual improvement of processes. Lee hopes that, as the client base grows and efficiencies are realized through AI‑driven automation, the facility will achieve financial independence before the six‑year grant period concludes.
Training the Next Generation of Scientists
Beyond service provision, the foundry serves as a training ground. Graduate students, postdoctoral fellows, and even undergraduates receive hands‑on experience in RNA manipulation, AI‑assisted design, and regulatory compliance. Lee envisions these trainees becoming the “first generation of people to think about RNA as a tool for whatever problem they’re trying to solve,” thereby seeding a workforce capable of applying RNA technology to challenges ranging from disease treatment to climate‑resilient agriculture.
Facility Description and Operations
A walk through AIRFoundry reveals a bustling, sterile laboratory lined with automated liquid handlers, nucleic‑acid synthesizers, and analytical instruments such as capillary electrophoresis and mass spectrometry stations. The layout supports a seamless workflow: from computational design (augmented by AI) to chemical synthesis, purification, formulation, and final quality testing. Strict environmental controls ensure that the RNA products meet the high purity standards required for both therapeutic and agricultural use.
Conclusion / Outlook
The NSF AIRFoundry at the University of Pennsylvania encapsulates a forward‑looking model for accelerating RNA innovation. By marrying cutting‑edge synthesis infrastructure with artificial intelligence, a clear democratization mission, and a diverse project portfolio spanning fish vaccines, plant heat‑shock protection, and beyond, the foundry aims to transform RNA from a niche laboratory reagent into a versatile, widely accessible tool. If successful, it could not only reinforce U.S. leadership in biotechnology but also provide scalable, sustainable solutions to pressing global challenges in health, food security, and environmental stewardship.